SecBot SecBot
8-K ·Filed Nov 4, 2026

DNTH

Dianthus Therapeutics, Inc. /DE/
NEUTRAL
Impact 4/10
Horizonmonths Processed12d 7h ago SEC0001690585-26-000039
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Key near-term catalysts are the Phase 2 MoMeNtum MMN top-line results in December 2026 and CAPTIVATE Part A CIDP results by YE 2027. The 75% interim response rate in CAPTIVATE supports the program's potential, but the stock remains a binary event-driven story with no approved products or revenue.

DirectionNeutral
Confidencehigh
Horizonmonths

Price Chart

Loading chart...

Executive Summary

Dianthus Therapeutics reported Q3 2026 financial results with a net loss of $46.6M ($0.81 per share), wider than the $36.8M loss in Q3 2025 but narrower on a per-share basis due to a higher share count. The company highlighted a 75% response rate in the CAPTIVATE CIDP trial interim analysis and maintained a $1.2B cash runway into 2030. No revenue or EPS consensus was provided for a verdict, but the net loss per share improved year-over-year from -$0.97 to -$0.81.

Key Financial Metrics

EPS
−$0.81
Revenue
$1.2M
est $389.0K · +211.1% · +205.6% YoY

Key Facts

  • Net loss for Q3 2026 was $46.6M or $0.81 per share, vs $36.8M or $0.97 per share in Q3 2025
  • Cash and investments of approximately $1.2B as of September 30, 2026, providing runway into 2030
  • 75% response rate observed in interim responder analysis of Phase 3 CAPTIVATE trial in CIDP
  • Phase 2 MoMeNtum trial in MMN top-line results on track for December 2026
  • Phase 3 EMERGE trial in gMG initiated in June 2026, top-line results expected in 2H 2028
  • DNTH212 Phase 1 SAD Part A healthy volunteer data expected in Q1 2027
  • DNTH312 on track to be Phase 1 ready by YE 2027
  • R&D expenses were $45.6M for Q3 2026, up from $32.5M in Q3 2025
  • G&A expenses were $14.1M for Q3 2026, up from $8.2M in Q3 2025
  • License revenue was $1.2M for Q3 2026 vs $0.4M in Q3 2025

Financial Impact

Net loss of $46.6M in Q3 2026, wider than $36.8M in Q3 2025; cash position stable at $1.2B

net losscash positionR&D expensesG&A expenses

Risk Factors

  • Clinical-stage biotech with no approved products or commercial revenue
  • Net loss widening year-over-year as R&D spending increases for multiple trials
  • All pipeline candidates are investigational and may fail in later-stage trials
  • Long timelines to potential approval: gMG Phase 3 results not expected until 2H 2028

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (24 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001690585-26-000039
Document: dnth-20261104.htm0001690585-26-000039
Document: 0001690585-26-000039-index-headers.html0001690585-26-000039
Document: 0001690585-26-000039-index.html0001690585-26-000039
Document: 0001690585-26-000039.txt0001690585-26-000039
8-K Data (Synthetic)0001690585-26-000039

Track record

23 reports on DNTH

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
  2. Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 4/10 Viewing No price data
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
  5. Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
  6. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
  7. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
  8. Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
  9. Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
  10. Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 9h 30m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026